Aeris Capital et al. invest in Affimed Therapeutic series-D

Participating investors include BioMedInvest, LSP Life Sciences Partners, Novo Nordisk and Orbimed. The company will use the funding for the clinical development of two new tetravalent bispecific antibody format (TandAb) products, AFM11 and AFM13.

Affimed Therapeutic previously received funding rounds in 2003 (€2m), 2007 (€25m), 2008 (€5m) and 2010 (€20m).

Company
Spun out of the German Cancer Research Centre (DKFZ), Heidelberg, and led by CEO Dr Adi Hoess, Affimed has generated a range of drug candidates based on its proprietary TandAb antibody technology. The drugs focus on the treatment of oncological and anti-inflammatory diseases. Affimed employs 30 people.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• DACH
• Germany